Oxalipatin-Based Chemotherapy for Grade 3 Neuroendocrine Carcinoma after Failure of Platinum- Based Chemotherapy

#714

Introduction: Cisplatin/etoposide regimen is the recommended first line treatment for poorly differentiated grade 3 neuroendocrine carcinoma (G3-NEC). There is no standard second line.

Aim(s): We analyzed the antitumor efficacy of oxaliplatin-based chemotherapy (Ox-bC) in G3-NEC patients (pts).

Materials and methods: This is a single center retrospective analysis of consecutive G3-NEC pts treated with Ox-bC between December 2003 and June 2012. Primary endpoint was progression-free survival (PFS) and secondary endpoints were overall survival (OS), response rate (RR) and safety.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author:

Authors: Hadoux J, Guigay J, Malka D, Planchard D, Boige V,

Keywords: neuroendocrine carcinoma, grade 3, oxaliplatin,